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Over the last decade it became broadly recognized that adipokines and thus the fat tissue
compartment exert a regulatory function on the immune system. Our own group described
the pro-inflammatory function of the adipokine leptin within intestinal inflammation in a vari-
ety of animal models. Following-up on this initial work, the aim was to reveal stimuli and
mechanisms involved in the activation of the fat tissue compartment and the subsequent
release of adipokines and other mediators paralleled by the infiltration of immune cells.
This review will summarize the current literature on the possible role of the mesenteric fat
tissue in intestinal inflammation with a focus on Crohn’s disease (CD). CD is of particular
interest in this context since the transmural intestinal inflammation has been associated
with a characteristic hypertrophy of the mesenteric fat, a phenomenon called “creeping
fat.” The review will address three consecutive questions: (i) What is inducing adipocyte
activation, (ii) which factors are released after activation and what are the consequences for
the local fat tissue compartment and infiltrating cells; (iii) do the answers generated before
allow for an explanation of the role of the mesenteric fat tissue within intestinal inflam-
mation? With this review we will provide a working model indicating a close interaction in
between bacterial translocation, activation of the adipocytes, and subsequent direction of
the infiltrating immune cells. In summary, the models system mesenteric fat indicates a
unique way how adipocytes can directly interact with the immune system.
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WORKING MODEL
WHAT IS INDUCING ADIPOCYTE ACTIVATION?
Classically, adipose tissue was categorized as the site of energy stor-
age and release. But this concept changed profoundly within the
last decades when adipose tissue has been identified as a potent
endocrine organ with effects on metabolism and immunity. Fat
tissue is a powerful producer of fatty acids, classical cytokines,
chemokines, and adipokines, to name just some of the factors
released. Considering that adipose tissue accounts for 10–20% of
the body weight in males and 20–30% in females (1) one can well
accept that this endocrine tissue has been studied more closely for
its impact on body homeostasis and immune cell regulation.
Adipose tissue comprises not only mature adipocytes but har-
bors a variety of other cells including adipocyte precursor cells
(preadipocytes), fibroblasts, and immune cells including T cells
and macrophages. The size of adipocytes varies according to their
lipid content and is linked to the function of the cells, with larger
adipocytes usually being more active with regard to their metabolic
activity and adipokine production (2). In mammals two kinds of
adipose tissue exist. Brown adipose tissue plays an important role
in thermogenesis in particular in neonates whereas the main adi-
pose tissue present in adults belongs to the white adipose tissue.
Hence this review will focus on white adipose tissue, which is dis-
tributed throughout the body mainly at two different sites, the
subcutaneous and the visceral compartment. Subcutaneous fat is
present as hypodermis under the skin and visceral adipose tissue
surrounds organs in the abdominal cavity. Both compartments
exert different competence with regard to metabolic and immune
regulating function with the increase in metabolic diseases in par-
ticular being linked to the visceral fat (3). The visceral fat can be
subdivided into omental fat which surrounds the intestine super-
ficially, retroperitoneal fat near the kidney and the mesenteric fat
in close proximity to the intestine (4).
In Crohn’s disease (CD), a specific hypertrophy of the mesen-
teric fat adjacent to the inflamed intestinal segments occurs. Burrill
J. Crohn himself reported in the thirties of the last century, that
mesenteric fat is increased and closely attached to inflamed parts
of the colon and termed this observation “creeping fat,” an alter-
ation unique to CD patients. Since then this initial report was
verified by different techniques and groups over the last years (5–
7). CD is a chronic intestinal inflammation that mainly affects the
terminal ileum and the proximal large bowel, but can potentially
involve any location of the alimentary tract. The etiology of the
disease is not finally understood, and current therapeutic strategies
are not curative, although they are effective in alleviating clinical
symptoms.
But even though the close contact of creeping fat and inflamed
intestinal segments in CD has been known for decades, the role
of this fat hypertrophy and the consequences of this local adipose
tissue increase for the ongoing intestinal inflammation are not
understood yet (8). With the perception regarding the multiple
functions of adipose tissue changing in the recent years, the inter-
est in deciphering the link between the mesenteric fat hypertrophy
in patients and the intestinal inflammation arose. Even though the
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interaction between the sites is still not completely understood,
there is solid evidence, that they affect each other.
It is not known during which stage of disease the mesenteric
fat hypertrophy develops, but one underlying cause expected to
be related to the local adipose tissue remodeling is the altered
intestinal barrier function and subsequent bacterial translocation.
In CD, as well as in experimental models of intestinal inflamma-
tion, such increased translocation of bacteria into the intestinal fat
occurs. This finding is already leading to our first questions: how
does inflammation arise in mesenteric adipose tissue in the setting
of CD?
Bacterial translocation represents a possible mechanism as
altered epithelial permeability is a feature of CD disease and
bacteria are more frequently present in both mesenteric adi-
pose tissue and mesenteric lymph nodes of CD patients (9, 10).
Similarly, in experimental models of inflammatory bowel dis-
ease (IBD) such as dextran sulfate sodium (DSS)-induced col-
itis or indometacin-induced ileitis bacterial translocation was
enhanced (10, 11).
But one has to bear in mind that bacterial translocation is not
unique to states of intestinal inflammation, however it is increased
when compared to healthy subjects where bacterial translocation
to mesenteric adipose tissue can equally be detected (10).
Concerning the mechanisms leading to increased permeability
in intestinal inflammation several factors are discussed for bac-
teria. First, the intestinal barrier consists of the secreted mucus
barrier as well as the cellular barrier (12). The barrier formed by
mucus and here in particular the dysregulation of defensin produc-
tion plays a critical role in CD (13–15). Thus targeting alterations
in the composition of these anti-microbial peptides might serve as
therapeutic strategy in the future (16).
In addition, defects in the cellular barrier have been reported.
Söderholm and colleagues detected augmented tight junction
permeability in the intestine of CD patients (17). Zeissig and col-
leagues linked changes in the expression of claudins 2, 5, and 8
to reduced strands of tight junctions in active disease accompa-
nied by an increased rate of epithelial cell apoptosis in active CD
(18). While the increased incidence of bacterial translocation in
CD patients is commonly accepted, the mechanisms allowing for
bacterial translocation are not finally dissected. In fact, the under-
lying mechanisms might even be different in ileal and colonic CD,
as depicted in detail by Gersemann and colleagues in a recent
review (16). Leading us to the question what might be the con-
sequence of increased bacterial translocation into the adjacent
adipose tissue?
Besides their energy storing capacity and their secretory activ-
ity, adipocytes share commonalities with immune cells. An initial
link between adipocytes and innate immunity was a report, that
depicted the plasticity of murine preadipocytes which could con-
vert to macrophage-like cells, characterized by the expression
of macrophage markers like F4/80 and Mac-1 as well as co-
stimulatory molecules including CD80 and CD86 (19). In the
meantime further similarities have been revealed. For instance,
macrophages, preadipocytes, and adipocytes express different
classes of pattern recognition receptors enabling them to respond
to microbial moieties with either increased or decreased secretion
of immunological active molecules (11, 20, 21).
Adipose tissue responsiveness to endotoxin
Already in the seventies of the last century it was shown that adi-
pose tissue is responsive to bacterial compounds such as endotoxin
as assessed by alterations in lipid metabolism in rodents following
injection of this bacterial antigen with differences in the grade of
lipolysis between subcutaneous and mesenteric fat (22–24). This
sensitivity of fat toward bacterial components was well studied
during the following decades, but again with an emphasis on the
effects on metabolism (25, 26).
Taking into account that the availability of energy is a prerequi-
site for immune function, in the following years the consequences
of adipose tissue stimulation by bacterial products for the immune
system were studied. Local LPS application induced the release of
glycerol from adipose tissue surrounding lymph nodes, thus sup-
porting the initiation of the immune response and linking the
capacity of adipose tissue to detect bacterial products (27, 28).
Again, these studies mainly focused on the biological effects of
stimulation and not on the mode of antigen recognition involved.
Toll-like receptors
In 2000 Lin and coworkers demonstrated that adipocytes express
Toll-like receptors (TLR) (29), a group of transmembrane recep-
tors that sense highly conserved microbe-associated molecular
patterns (30).
So far a total of 13 TLR have been identified, with 10 and 12
functional in humans and mice (31). These receptors recognize
conserved structures that are not present in the host, but more or
less frequently present in viruses, fungi, or bacteria and include for
example zymosan, flagellin, nucleic acids, and LPS (32).
Stimulation of these innate receptors by their specific lig-
ands is followed by the activation of signaling pathways such
as nuclear-factor kappaB (NFκB) or mitogen-activated protein
kinase (MAPK), resulting in the production of pro-inflammatory
cytokines in immune cells (33). Lin and colleagues described
not only the expression of TLR on adipocytes and preadipocytes
but further revealed that the activation of TLR4 resulted in an
increase of TLR2 expression in adipocytes, already suggesting that
the response to bacterial products is well orchestrated in these
cells (29).
Further studies confirmed that adipocytes and preadipocytes
express numerous receptors from the TLR family. We and others
have provided evidence for the functional expression of TLRs on
adipocytes and preadipocytes. For example stimulation of TLR4 in
adipocytes and preadipocytes by LPS induced increased produc-
tion of classical cytokines and chemokines including IL-6, MCP-1,
and TNFα (34–36).
When characterizing TLR expression and responsiveness, our
group revealed that leptin deficiency, an adipokine initially
described as a satiety signal, altered TLR expression and cytokine
release following stimulation (35). This observation was con-
firmed by Kim and colleagues who reported an increased TLR
expression not only in leptin-deficient mice, but equally in mice
fed a high-fat diet (37). This link between leptin and TLR expres-
sion could be confirmed in human cells where expression of TLR2
on monocytes is enhanced in the presence of high levels of leptin.
An effect, that might contribute to the increased immune response
seen in obesity (38). Furthermore, this observation is bridging the
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energy status of the organism to the initial concept, that respon-
siveness of adipose tissue to bacterial antigens is linked to the
regulation of energy supply.
In fact the interplay of energy supply or nutrition and TLR
expression in adipocytes forms a subject of recent research in the
field of metabolic diseases. For example supply of citrus flavonoid
is not only beneficial in obesity-related diseases but was further-
more linked to its’ modulating effects on TLR2 expression (39).
Bearing such mutual interactions between energy supply and TLR
expression in mind it seemed a logical consequence to ask whether
pathogen-associated molecular patterns present the sole ligands
for TLR?
One group reported in 2009, that at least TLR4 on adipocytes
can be stimulated directly by fatty acids leading to the activation
of NF-κB with different fatty acids inducing specific profiles of
released adipokines (40). Indeed it was an intriguing thought, that
in altered states of fatty acid release by the adipose depot, i.e. in
various states of nutritional supply, the TLR signaling pathway
is involved in the modulation of the endocrine activity of the
fat tissue compartment. However, in 2009 this view was negated
by Erridge and Samani who pointed out that these studies deal-
ing with TLR4-specific stimulation following supply of fatty acids
in vitro might be hampered by LPS contamination of the fatty acids
employed or the proteins used for solving them, thus questioning
direct effects of the fatty acids on TLR stimulation (41). This later
view is supported by a study that investigated fatty acid effects on
TLR activation where no direct stimulation of TLR2 and TLR4 by
dietary saturated and unsaturated fatty acids was measured (42).
Not only the direct effect of altered fatty acid levels in adi-
pose tissue in the course of diet or infection on TLR has not been
deciphered yet. Conflicting reports about the link between the
nutritional status and the TLR expression exist. While recently
one report stated that mRNA levels of TLR2, TLR6, and TLR7 are
decreased in mice fed a high-fat diet (43), other studies provide
evidence that TLR1-9 and TLR11-13 are up-regulated in murine
adipose tissue following obesity-induction by a high-fat diet (37).
Thus deciphering the impact of TLR expression on the function of
adipose tissue cells is still a field full of open questions that requires
further clarification. However, there is an additional class of recep-
tors present in adipocytes that further supports their commitment
to the innate immune system, the so-called nucleotide-binding
oligomerization domain (NOD)-like receptors.
The nucleotide-binding oligomerization domain-like receptors
Like TLR, NOD-like receptors detect highly conserved non-self
antigens. This group comprises the subfamilies of NOD, NLR
family pyrin-domain-containing proteins (NLRP), NLR family
CARD-domain containing (NLRC), neuronal apoptosis inhibitor
factors (NAIP), NLRX, and MHC II transactivator (CIITA), with
all of these receptors being localized in the cytosol (32, 44).
NOD1 and NOD2 were the first members of the NLR family
to be described and are responsive to subunits of peptidogly-
cans (45, 46). In CD these receptors gained particular interest,
since polymorphisms in NOD2 were linked to an increased risk
of developing CD (47, 48). Our group was the first to show that
preadipocytes express not only NOD1 and NOD2 receptor spe-
cific mRNA but functional cytosolic receptors (20). Since then,
several groups confirmed the presence of functional NOD recep-
tors in fat cells from mice and man and postulated both, effects
on immune response and insulin sensitivity as a consequence of
stimulation (49, 50).
A recent study depicts that NOD activation is linked to
adipocyte differentiation. In a murine cell line differentiation of
preadipocytes to mature adipocytes was decreased by NOD1- but
not NOD2-specific stimulation. The authors noticed some species
specific differences when they tested this observation in human
cells where activation of either of the two receptors, NOD1 or
NOD2, suppressed maturation of adipose tissue derived stem cells
to adipocytes (51).
Even though it is well accepted that genetic variants of NOD2
are associated with a higher susceptibility to CD (52) the conse-
quence of NOD2 stimulation by bacterial products is not finally
understood. Our own group noticed regulation of NOD2 mRNA
in preadipocytes following stimulation of NOD1 or via pro-
inflammatory cytokines. But unlike stimulation of NOD1 no
induction of cytokine release took place thereafter (20). This is
in line with the current concept, that NOD2 activation might
be a regulator of TLR-induced cytokine production. For exam-
ple in human dendritic cells loss of functional NOD2 results in
an increased IL-23 production induced by stimulation with E. coli
(53). In a study published this year, the effect of the NOD2 vari-
ants on bacterial translocation was characterized in patients. As
compared to controls bacterial mRNA was more frequent in the
blood of patients carrying either a NOD2- or an ATG16L1-variant
genotype. In addition, the presence of bacterial DNA was related to
disease activity and in patients with NOD2 variants the phagocytic
and bactericidal activity of blood neutrophils was decreased (54).
Even though this study omitted any information about mesen-
teric adipose tissue it is tempting to speculate that variants of
CD susceptibility genes might alter responses therein to bacterial
products. But what mechanisms can be activated in adipocytes
following the stimulation of the innate receptors? As mentioned
before, adipose tissue is the source of a plethora of mediators which
will be presented together with information about the biological
consequences of the release in the next section.
WHICH FACTORS ARE RELEASED BY ADIPOCYTES AFTER ACTIVATION
ANDWHAT ARE THE CONSEQUENCES FOR THE LOCAL FAT TISSUE AND
MACROPHAGES COMPARTMENT
The infiltration of mesenteric adipose tissue by macrophages was
initially described in murine models of obesity (55, 56), an obser-
vation subsequently confirmed in humans (57, 58). About 30% of
transcripts in mesenteric adipose tissue that correlated strongest
with obesity were inflammatory or macrophage specific (55). The
infiltration of macrophages into the inflamed mesenteric adi-
pose tissue represents a cardinal feature of creeping fat in CD
(59). Although fat wrapping is not typically observed in animal
models of colitis, macrophage infiltration of mesenteric adipose
tissue contiguous to sites of intestinal inflammation has been
described (60, 61).
Activation of the mesenteric adipose tissue results in the release
of cytokines (e.g., IL-6, TNFα), chemokines (e.g., MCP-1/CCL2,
Rantes/CCL5), adipokines (e.g., leptin, adiponectin, resistin, vis-
fatin), but also fatty acids (26, 62–64). Furthermore, preadipocytes
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have the potential to differentiate into macrophage-like cells
that express macrophage markers like F4/80, Mac-1, CD80, or
CD86, and are capable to phagocytose microorganisms (19). In
mesenteric adipose tissue of patients with CD a variety of such
potent molecules can be detected (59, 65–67) thereby influencing
macrophage recruitment and polarization.
In parallel to T helper cells the concept of macrophage polariza-
tion to either classically activated M1 macrophages or alternatively
activated M2 macrophages was established. M1 macrophages pro-
duce pro-inflammatory cytokines such as IL-1β, IL-6, and TNFα,
as well as effector molecules including reactive oxygen species or
nitric oxide. In contrast, M2 macrophages express high amounts
of IL-10, scavenger-, mannose-, and galactose-type receptors,
are involved in Th2 cell activation and regulate extracellular
matrix molecule synthesis, wound repair, and tumor progression.
However, it is well accepted that in vitro generated M1 or M2
macrophages represent extreme states on a continuum with tis-
sue macrophages displaying phenotypes comprising hallmarks of
both (68–70). Adipose tissue macrophages are characterized by the
expression of M2 surface markers like CD163, CD206, CD209, and
CD200, a high phagocytic activity, and the secretion of IL-10 and
IL-1 receptor antagonist (IL-1Ra). They release pro-inflammatory
molecules including TNFα, IL-6, IL-1, MCP-1, and MIP-1α in
quantities higher than in vitro generated M1 macrophages. These
macrophages cluster around necrotic adipocytes indicating a func-
tional role in the clearance of extracellular lipid and cellular
debris while they also contribute to adipose tissue inflammation
and metabolic dysfunction by inflammatory cytokines (71, 72).
In obesity the adipose tissue macrophage phenotype is skewed
even further toward M1 polarization (73, 74), whereas in CD
adipose tissue macrophages show an increased expression of M2
markers (75).
In the following, we will discuss molecules that are secreted by
activated preadipocytes or adipocytes under inflammatory condi-
tions with the potential to recruit macrophages and modulate their
phenotype or function. If LPS was used as an activating stimulus,
it was derived from E. coli.
IL-6 and TNFα
Both IL-6 and TNFα are key players in inflammation and their role
in the pathophysiology of CD is well established. IL-6 serum lev-
els correlate with disease severity and localization (76). Estimated
10–30% of circulating IL-6 is released from adipose tissue (77).
Increased TNFα levels have been observed in serum and intestine
of CD patients, more important, neutralizing TNFα represents an
approved treatment (78–81). Both IL-6 and TNFα are released
by preadipocytes and adipocytes upon stimulation with LPS (62,
63). Regarding IL-6, its expression is increased in the mesenteric
adipose tissue in TNBS colitis and inflammation is accompanied
by macrophage infiltration (60, 61). However, in inflamed mesen-
teric adipose tissue of CD patients IL-6 expression seems not to
be significantly higher than in other inflammatory conditions like
colorectal cancer (CC) or diverticulitis (67, 82).
IL-6 exerts direct chemotactic effects on monocytes by induc-
ing integrin expression, cell attachment, and transmigration
through the endothelium (83–85). Whether IL-6 itself modulates
macrophage phenotype and function is not reported yet. But in
preliminary studies we observed that at least in vitro the presence
of IL-6 directs macrophages to an anti-inflammatory phenotype
characterized by expression of CD163 and release of IL-10 (unpub-
lished data). However, IL-6 might influence the polarization of
adipose tissue macrophages via regulation of adipokine secre-
tion. For example, IL-6 in combination with soluble IL-6 receptor
inhibits adiponectin expression in 3T3-L1 adipocytes and primary
human adipocytes. Similarly, TNFα down-regulates adiponectin
secretion paralleled by an increase in leptin expression (86–88).
The impact of TNFα signaling on macrophage polarization is
supported by studies in TNF-receptor 1 (TNFR1) and TNFR2
deficient mice. On a high-fat diet, they show increased weight
gain and adipose tissue macrophage infiltration. Surprisingly, the
expression of pro-inflammatory cytokines like IL-6 and MCP-1 is
reduced paralleled by a skew of adipose tissue macrophages from
M1 to M2 polarization (89).
A further indirect evidence that TNFα is of significance
for macrophage polarization is the observation that the anti-
TNFα antibodies infliximab and adalimumab induce M2-like
macrophages in a mixed lymphocyte reaction. These cells inhibit
T-cell proliferation, secrete IL-10, and display an up-regulation of
the M2 marker CD206. However, the observed effect is probably
not only mediated by neutralizing TNFα but also by Fcγ-receptor
mediated binding of TNFα-antibody complexes (90).
C-reactive protein
The acute phase reactant C-reactive protein (CRP) is widely used
in clinical routine as a biomarker of inflammation in both infec-
tious and autoimmune diseases. In CD serum CRP levels do not
only indicate acute inflammation but also have predictive value
regarding the course of disease (91). While liver is considered
to be the main source of CRP (92) evidence is mounting that
adipose tissue is another important source. Circulating CRP lev-
els increase with BMI in obese patients (93) while in CD CRP
levels correlate with mesenteric fat density measured by CT entero-
graphy (5). Recently, elevated CRP expression was demonstrated
within mesenteric adipose tissue of CD patients compared to
healthy controls and patients with ulcerative colitis (UC). Adi-
pose tissue expression and plasma levels correlated indicating that
adipose tissue might be an important source of total circulating
CRP. Interestingly, this elevated CRP expression was paralleled
by increased bacterial translocation to mesenteric adipose tissue
and lymph nodes. In vitro, adipocytes release CRP after stimula-
tion with TNFα, IL-6, LPS, and E. coli, but not Pam3Cys (a TLR2
ligand), MDP (a NOD2 ligand) or Lactobacillus spp. Thus, local
cytokines and translocalized gram-negative bacteria may synergize
to promote CRP expression in mesenteric adipose tissue (10, 93).
C-reactive protein binds to cell wall components of different
bacteria, damaged cells, and nuclear autoantigens. In consequence,
the classical complement cascade is activated leading to opsoniza-
tion of the bound antigens. Furthermore, CRP itself binds to
Fcγ-receptors on immune cells like monocytes and macrophages
(92). Regarding its effect on monocytes and macrophages conflict-
ing results were published. It was reported that CRP in synergy
with LPS induces both pro-inflammatory and anti-inflammatory
cytokines like IL-1β, IL-6, TNFα (94), and IL-1Ra in human mono-
cytes (95, 96). For human alveolar macrophages both stimulatory
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and inhibitory effects of CRP on the release of IL-1α, IL-1β,
TNFα, and IL-1Ra were described (95, 97). Incubation of human
monocyte-derived macrophages or isolated rat macrophages with
human CRP followed by LPS stimulation resulted in a decreased
IL-10 secretion (98), whereas in mice treatment of macrophages
with human CRP induced IL-10 production (99). This might be
due to species differences in the role of CRP as an acute phase
reactant.
Regarding macrophage polarization, incubation of human
monocytes with CRP for 7 days resulted in pro-inflammatory
macrophages characterized by a high expression of TNFα, IL-12,
CCR2, MCP-1, and IL-1. In parallel less cells expressed M2 mark-
ers like CD206, CD163, and IL-10 even if primed before with IL-4
(100). On the contrary, it was described that CRP treatment of
human monocyte-derived macrophages induced M-CSF release,
a factor well known to polarize macrophages to an M2 phenotype
(101). These discrepancies will have to be addressed in the future.
MCP-1 and RANTES
RANTES/CCL5 and MCP-1/CCL2 are both chemokines secreted
from preadipocytes or adipocytes upon stimulation with LPS
(62–64). Whereas RANTES/CCL5 is up-regulated in mesenteric
adipose tissue of CD, MCP-1 is elevated in tissue from obese
patients (66, 67, 102).
MCP-1 is an important macrophage chemoattractant in several
inflammatory conditions and various tissues (103, 104). Evidence
in the literature suggests that MCP-1 and its receptor CCR2 are
relevant factors for macrophage recruitment and accumulation in
inflamed adipose tissue. For instance, genetic ablation of MCP-1
or its receptor resulted in a decrease in obesity-induced adipose tis-
sue inflammation and macrophage infiltration, the opposite was
observed for MCP-1 over-expression (105–107). However, data
on this topic are conflicting as other reports did not describe
such an effect in MCP-1 knock-out mice arguing that MCP-
1 is at least not critical for macrophage infiltration to adipose
tissue (108, 109).
In murine tumor models blockage of MCP-1 does not affect
overall tumor associated macrophage number, but results in a skew
of macrophage phenotype with reduced expression of M2 markers
(CD206 and arginase 1) and slight up-regulation of the M1 marker
inducible nitric oxide synthase (iNOS) (110). Together with IL-
6, MCP-1 favors survival of human CD11b+ peripheral blood
mononuclear cells (PBMC) and augments CD206 expression as
well as the total number of CD14+/CD206+ cells an effect medi-
ated via inhibition of caspase-8 cleavage and enhanced autophagy
(111). Besides MCP-1, RANTES and its receptor CCR5 may be
involved in adipose tissue macrophage recruitment and polariza-
tion. For example, CCR5 knock-out mice display reduced numbers
of adipose tissue macrophages accompanied by a skew toward an
M2 phenotype (112).
M-CSF and GM-CSF
M-CSF is expressed significantly higher in mesenteric adipose tis-
sue from patients with CD compared to diverticular disease and
CC and its over-expression is associated with adipocyte hypertro-
phy (67, 113). Studies applying M-CSF knock-out mice indicate
its importance for normal macrophage differentiation in various
tissues (114). Regarding macrophage polarization, highly pure
subsets of anti-inflammatory M2 macrophages can be obtained
by differentiating human mononuclear cells in the presence of
M-CSF (115). These cells stably express CD163 and IL-10 as a
signature cytokine even in presence of strong co-stimuli such
as IFNγ or CD40L. They release only relatively low amounts of
pro-inflammatory cytokines like TNFα, IL-1β, IL-6, and fail to
secrete IL-12/IL-23 (115, 116). This is accompanied by a slower
IκBα degradation and recruitment of NFκB to its nuclear binding
sites (117).
At least in vitro, opposite effects can be observed for GM-CSF
polarizing human macrophages toward an M1 phenotype (115–
118). Both M-CSF and GM-CSF seem to act as opponents on
human macrophage function as they suppress the cellular response
of each other when added to the same monocyte/macrophage
population (119, 120). Whether GM-CSF expression is altered
in mesenteric adipose tissue in CD has not been investigated
yet. In murine obesity models, GM-CSF seems to be relevant for
macrophage recruitment to mesenteric adipose tissue where it is
highly expressed. GM-CSF knock-out mice display reduced num-
bers of adipose tissue macrophages accompanied by lower levels
of pro-inflammatory cytokines (121). Thus, the local M-CSF/GM-
CSF ratio might be a factor modulating macrophage polarization
during inflammation. A high local expression of M-CSF might
add to the enrichment of CD163+ M2 macrophages observed in
the creeping fat of CD (75).
Leptin, adiponectin, resistin, and visfatin
The adipokine leptin is up-regulated in the mesenteric adipose
tissue of CD and UC patients compared to CC and diverticular
disease (65, 67). In contrast to other adipokines like adiponectin,
resistin, and visfatin, which are all down-regulated leptin expres-
sion is not affected or even enhanced in long term LPS-activated
adipocytes (64). Leptin seems to have direct effects on intesti-
nal barrier function. Increased levels affect mucin production and
increase colonic tight junction permeability (122–124). Further-
more it promotes growth of colonic epithelial cells (125). All
these factors contribute to the integrity of the intestinal barrier
hence leptin deficiency results in an increased bacterial transloca-
tion to the blood (126). Regarding its effects on monocytes and
macrophages, leptin promotes phagocytosis and release of pro-
inflammatory cytokines (e.g., IL-6, TNFα) and reactive oxygen
species (127–129). Furthermore, it activates vascular endothe-
lial cells resulting in up-regulation of adhesion molecules thereby
facilitating diapedesis of monocytes (130). Data from our group
and others indicate that leptin also modulates macrophage polar-
ization. Culturing human monocytes in the presence of leptin
results in an increase in the expression of the M2 surface mark-
ers CD14, CD206, and CD209 accompanied by relatively high
expression of TNFα, IL-6, IL-1β, and IL-10 (131). Similarly, we
observed an increased secretion of TNFα, IL-6, and IL-10 after
leptin stimulation of in vitro generated M1 and M2 macrophages
using GM-CSF or M-CSF, respectively. This was paralleled by
an enhanced phagocytic and chemotactic capacity (75). Besides,
leptin induces GM-CSF secretion at least in murine peritoneal
macrophages that might affect their polarization in an autocrine
manner (128). Taken together, leptin effects could contribute to
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FIGURE 1 | Working model of factors contributing to increased bacterial
translocation and adipose tissue activation in Crohn’s disease.
Alterations in mucus and at the cellular level of the intestinal barrier all
contribute to increased translocation of bacterial cells. Bacteria and
microbe-associated molecular patterns reach adipose tissue where the
subsequent stimulation of pattern recognition receptors affects the ballance
of cytokines and adipokines released at this site. In consequence
macrophages are recruited and polarized either toward a pro-inflammatory
M1 phenotype (e.g., in the lamina propria, orange color) or a regulatory M2
phenotype (e.g., in the mesenteric fat, blue color).
the particular phenotype of adipose tissue macrophages displaying
hallmarks of both M1 and M2 polarization (72).
Adiponectin belongs to C1q/TNF molecular superfamily and
shares structural similarities with TNFα, TNFβ, and CD40L
(132, 133). Yamamoto et al. reported that adiponectin expres-
sion was significantly increased in the creeping fat of patients
with CD nearby inflamed intestine (134). Similarly, Paul et al.
detected increased adiponectin expression in CD creeping fat (67).
In vitro adiponectin expression is not altered in mature adipocytes
stimulated by LPS. However, differentiation of preadipocytes to
adipocytes is inhibited with a consecutive reduction in adiponectin
expression (64). The effect of adiponectin on macrophages
seems to be anti-inflammatory as it suppresses LPS induced
TNFα and IL-6 release, increases IL-10 secretion and impairs
the phagocytic capacity (135, 136). Adiponectin inhibits several
pro-inflammatory pathways elicited by LPS, TNFα, and IL-6 in
human macrophages via the induction of anti-inflammatory pro-
teins (137). In creeping fat adiponectin levels correlated nega-
tively with IL-6 and CRP expression (134). Opposite to leptin
(130), adiponectin inhibits TNFα induced up-regulation of adhe-
sion molecules like VCAM-1, ICAM-1, and E-selectin on vascular
endothelial cells thereby preventing monocytes from attachment
(138, 139).
Several studies investigated the modulating effects of
adiponectin on macrophage polarization but with contradictory
results. Adiponectin has been identified to induce M2 markers
such as CD163, CD206, and CCL18 in both murine and human
macrophages (140, 141). In RAW264.7 macrophages, adiponectin
led to an M2 phenotype via an IL-4 dependent manner (142).
In contrast to these data, the analysis of an adiponectin-induced
transcriptome in human mononuclear cell-derived macrophages
showed an augmented expression of 28 of 46 strictly M1-
associated markers, whereas only 3 of 43 M2-associated markers
were increased (143). In the latter study both M1 cytokines like
TNFα and IL-6 and M2 cytokines such as CCL18 and CCL23 were
induced. Data from our group indicate that adiponectin alters
the phenotype and function of M1 and M2 macrophages dif-
ferentiated with either GM-CSF or M-CSF, respectively, with the
M2 phenotype being more susceptible. Adiponectin up-regulates
IL-10, IL-6, TNFα, and CD206 expression in M2 macrophages
thus leading to cells comprising both pro- and anti-inflammatory
potency as described for adipose tissue macrophages (75).
Circulating resistin levels are increased in IBD (144, 145).
Increased resistin expression was found in the mesenteric adi-
pose tissue of patients operated on CD and diverticulitis but
not CC (67). In human adipose tissue, resistin expression is 2.5
times higher in the omental than in subcutaneous fat with non-
fat cells being its main source (146, 147). In human PBMC and
macrophages, resistin expression can be induced by different stim-
uli such as TNF-α, IL-1, IL-6, and LPS (148, 149). But also LPS
stimulation of isolated human subcutaneous adipocytes results
in increased resistin expression (150). Furthermore, experimental
endotoxemia causes a strong rise in circulating resistin levels (149).
Resistin itself induces the secretion of pro-inflammatory cytokines
such as IL-1β, IL-6, IL-12, and TNFα in human PBMC and
macrophages (151, 152). Furthermore, it up-regulates adhesion
molecules like ICAM-1 and VCAM-1 as well as MCP-1 in human
endothelial cells facilitating monocyte recruitment (153). How-
ever, whether resistin directly modulates macrophage polarization
has not been investigated to our knowledge.
Visfatin is an adipokine preferentially expressed in visceral
adipose tissue (154). Its circulating levels are increased in IBD
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Table 1 | Summarizes alterations in CD adipose tissue as outlined in this review and provides a simplified working model to visualize adipose
tissue alterations in CD as compared to normal fat and the state of obesity.
Normal adipose tissue
Obesity CD mesenteric fat
- Bacterial translocation
- Pro-inflammatory milieu 
in the adjacent intestine
- Excess nutritions
- Bacterial translocation
Cellular alterations ↑ Adipocyte size ↓
↑ Adipocyte number ↑
↑ Local immune cells ↑
↑ M1 macrophages ↑
– M2 macrophages ↑
Mediators released ↑ IL-6 –
↑ TNFα ↑
↑ MCP-1 –
n.d. M-CSF ↑
↑ Leptin ↑
↓ Adiponectin ↑
↑ Resistin ↑
↑ Visfatin ↑
↑ C-reactive protein ↑
— RANTES ↑
↑ Free fatty acids n.d.
↑ Fetuin A n.d.
Legend Pro-inflammatory macrophage M1 Regulatory macrophage M2
Adipocyte Lymphocyte Fibroblast/preadipocyte
↑↓, increase or decrease as compared to fat from healthy controls; –, no alteration reported; n.d., not done.
In general an increase in adipose tissue mass is accompanied by higher production of a broad variety of mediators. Additionally, bacterial products are potent inducers
of various adipokines. Several of these mediators attract immune cells, leading to infiltration of the fat byT cells and macrophages. Differences in the relative presence
of the various mediators expressed by adipose tissue result in the diverse macrophage phenotypes dominating this compartment. While in obesity pro-inflammatory
M1 cells accumulate, in the mesenteric fat of CD anti-inflammatory M2 macrophages increase.
positively correlating with disease activity (145, 155, 156) but
also in other inflammatory conditions such as acute lung injury
(157), atherosclerosis (158), and rheumatoid arthritis (159). In
colonic biopsy specimens of IBD patients, adipocytes as well
as CD163+ macrophages from both submucosa and mesenteric
adipose tissue were identified as cellular sources of visfatin. In
human CD14+ monocytes, visfatin induced both pro- and anti-
inflammatory cytokines including IL-1β, IL-6, TNFα, IL-1Ra, and
IL-10, respectively. In GM-CSF differentiated macrophages how-
ever it induces only IL-6. Co-stimulatory molecules like CD80
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and CD40 were up-regulated in visfatin stimulated monocytes
leading to an increased stimulatory capacity in a mixed lympho-
cyte reaction. Furthermore, visfatin enhanced CD206 mediated
phagocytosis in human monocytes and appeared to be a potent
chemotactic factor for them (155). Thus one may consider vis-
fatin a potent activator of human monocytes. Whether visfatin
modulates macrophage polarization has not been investigated in
detail. Recently, it was reported that peritoneal macrophages of
visfatin−/−mice showed reduced iNOS expression and NO release
after LPS stimulation whereas visfatin treatment of RAW264.7 cells
results in an increase of iNOS mRNA and protein expression (160).
These finding indicate that visfatin might skew macrophages
toward an M1 phenotype.
Very recently, fetuin A has been discovered as a novel adipokine,
which could form the link to understand the above discussed con-
flicting reports concerning the activation of TLR4 by fatty acids.
Pal and colleagues assumed that fetuin A is an endogenous lig-
and through which fatty acids can stimulate TLR4 (161). Fetuin
A itself is released from adipocytes in response to excess lipids
in an NFκB dependent manner. Furthermore, it is capable to
attract macrophages and skew their phenotype from M2 toward
M1 polarization as it is described in obesity (161, 162). However,
different mechanisms might induce the macrophage phenotype in
the creeping fat of CD patients (75).
DO THE ANSWERS GENERATED BEFORE ALLOW FOR AN EXPLANATION
OF THE ROLE OF THE MESENTERIC FAT TISSUE WITHIN INTESTINAL
INFLAMMATION? – CONSEQUENCES FOR DISEASE
Adipose tissue is a multi potent organ with immune modulat-
ing capacity. In CD the normal state of local adipokine, cytokine
and cell networks seems to be imbalanced with increased influx of
immune cells and altered, usually increased, expression of immune
regulating mediators.
In CD mesenteric fat shows drastic alterations as compared to
health with a significant influx of M2-polarized macrophages and
decreased adipocytes size. Since most cells present in adipose tis-
sue express innate receptors we assume that the translocation of
bacteria and bacterial products that takes place in CD patients is an
initial cause for the mesenteric fat alterations. As a consequence of
the stimulation via activation of innate receptors the cytokine and
adipokine profiles and levels expressed in the mesenteric fat change
(see Figure 1). This altered milieu leads to attraction and switch in
phenotype of macrophages, an effect that might fuel the local alter-
ations. It might well be that this accumulation of immune cells and
their phenotypic conversion represents a protective mechanism of
the mesenteric fat to dampen the adjacent inflammation. On the
other hand, since pro-inflammatory adipokines are abundant in
the tissue another scenario would be, that due to defective response
mechanisms following bacterial stimulation the mesenteric fat in
CD patients is not a barrier to protect the body from the ongo-
ing intestinal inflammation but involved in the persistence of the
intestinal inflammation by increased release of for example leptin
and resistin.
Interestingly, some of the factors produced at higher levels in
CD fat are abundantly expressed in obesity as well (see Table 1
for alterations in mediator production as compared to health and
obesity). Thus, the unique feature of CD mesenteric fat cannot
be attributed to abundance of single agents or mediators but
seems to be a consequence of the altered proportions of the factors
presented in this article.
CONCLUDING REMARKS
With this review we aim to emphasize the critical interaction of
the adipose tissue and the immune system. In our view CD as well
as obesity form two representative examples. However, we would
like to suggest that this interaction is of vital significance for other
conditions.
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